ARKG icon

ARK Genomic Revolution ETF

20.67 USD
-0.13
0.62%
At close Apr 17, 4:00 PM EDT
After hours
20.67
+0.00
0.00%
1 day
-0.62%
5 days
5.14%
1 month
-11.89%
3 months
-14.27%
6 months
-15.04%
Year to date
-15.49%
1 year
-12.34%
5 years
-44.75%
10 years
-11.55%
0
Funds holding %
of 7,407 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

16% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 38

13% more call options, than puts

Call options by funds: $68.2M | Put options by funds: $60.3M

1% less funds holding

Funds holding: 235 [Q3] → 232 (-3) [Q4]

2.87% less ownership

Funds ownership: 54.81% [Q3] → 51.94% (-2.87%) [Q4]

18% less capital invested

Capital invested by funds: $699M [Q3] → $574M (-$125M) [Q4]

57% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 88

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for ARKG.

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Positive
Zacks Investment Research
1 month ago
Best-Performing ETFs of Last Week
Wall Street was upbeat last week, despite the release of hot January inflation data.
Best-Performing ETFs of Last Week
Negative
24/7 Wall Street
2 months ago
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year
Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years.
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year
Positive
ETF Trends
2 months ago
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.
Can Health Care ETFs Aid Your Portfolio?
Positive
24/7 Wall Street
2 months ago
Cathie Wood's Top Biotech Plays for February
Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.
Cathie Wood's Top Biotech Plays for February
Positive
ETF Trends
2 months ago
Under-the-Radar Opportunities in ETFs
Over recent years, investors have sought safety within mega-cap tech stocks while searching for alpha within disruptive technology trends like artificial intelligence. Most investors can agree the AI theme has long-term growth potential, and the current market sell-off is a short-term hiccup.
Under-the-Radar Opportunities in ETFs
Neutral
ETF Trends
2 months ago
ETF Prime: Islam Shares 2025's Top Trends and ETFs
On this week's episode of ETF Prime, Roxanna Islam, CFA, CAIA, head of sector & industry research at VettaFi, joined host Nate Geraci. The two discussed top ETF performers and trends this year as well as long-established asset managers finally joining the ETF industry.
ETF Prime: Islam Shares 2025's Top Trends and ETFs
Neutral
Bloomberg Markets and Finance
2 months ago
Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI
Chinese AI startup DeepSeek has released a new open-source AI model called R1 that can mimic human reasoning, rivalling or outperforming leading US developers on industry benchmarks. The release of R1 has sent shockwaves through the US tech industry, with companies like OpenAI and Meta analyzing how DeepSeek built its model and whether it did so as cheaply as claimed, and lawmakers trying to figure out how to compete with China's progress on AI.
Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI
Positive
Seeking Alpha
2 months ago
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends
I maintain a buy rating on ARK Genomic Revolution ETF (ARKG) due to improving momentum, potential lower interest rates, and a favorable M&A environment in 2025. Despite a 20% decline in 2024, ARKG's technical chart shows bullish potential with key support at $21-$22 and resistance at $28. ARKG is a small, actively managed ETF focused on genomics, with high exposure to small-cap stocks and a diversified mix of value, blend, and growth.
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends
Neutral
The Motley Fool
2 months ago
Here Are the 6 Largest Stock Holdings in All of Cathie Wood's ETFs Right Now
Asset management company Ark Invest offers nine different investment funds, eight of which are available as exchange-traded funds, or ETFs. They all have a different tech-related focus, such as robotics, biotechnology, or general innovation.
Here Are the 6 Largest Stock Holdings in All of Cathie Wood's ETFs Right Now
Charts implemented using Lightweight Charts™